I think the only thing that will help short term is...

I think the only thing that will help short term is demonstrated, consistent Daybue prescription increases and then NNZ in the long term.

If the meeting with the FDA goes well (I wish I knew when it was in September) it could save Neuren a substantial amount of money if the numbers required for the trial are reduced etc. It is a wide estimate for a phase 3 trial between 50-100 USD. That is a lot of money, especially as it was said in the latest webinar PMS would set the scene for the PH trial so it would most likely be a double saving of a bucket load of money relative to Neuren's current financial situation.

Even though the FDA meeting is about PMS only it will essentially set the template for PH and any other indications under the same branch of the FDA.

Then, we have the undisclosed indications, success in those must help and they could come anytime.

These were Jon's words in the Angelman webinar in August...

'as for discussions, I'm not going to specify big pharma but other pharmaceutical companies I've said before we've had already a number of discussions and we'll continue to have discussions but we need to getthrough that meeting in September before we'll say anything more concrete than that.

Ugly times with the share price but I ask what permanent difference would a buy-back make if the very soon-to-be-announced FDA meeting result was unfavourable or the undisclosed indications failed? Holders might dump on the rise of a buyback and would certainly bail with bad news so we would be right back where we started, wouldn't we?

I still have a gut feeling the company thinks it has things under control at this stage of proceedings and they know, like most of us, a lot is going to happen in the next 4 -5 weeks. Either way, positive or negative, it is going to be company-defining.